 TEL AVIV, Israel, Dec. 16, 2020 PRNewswire -- BioLineRx Ltd. NASDAQ: BLRX TASE: BLRX, a late clinical-stage biopharmaceutical Company focused on oncology, today announced results from the triple combination arm of the Companys COMBATKEYNOTE-202 clinical study evaluating... 